In 2019, FDA approved Piqray (alpelisib) in combination with fulvestrant to treat postmenopausal women and men with advanced HR-positive/HER2-negative breast cancer with a PIK3CA gene mutation that had occurred during or after treatment with AIs. This evidence concerns the gene ERBB2 and breast carcinoma.